{
  "CitationSubset": [
    "IM"
  ],
  "KeywordList": [],
  "GeneralNote": [],
  "OtherAbstract": [],
  "SpaceFlightMission": [],
  "OtherID": [],
  "InvestigatorList": [],
  "PMID": "18847401",
  "DateCompleted": {
    "Year": "2008",
    "Month": "12",
    "Day": "02"
  },
  "DateRevised": {
    "Year": "2008",
    "Month": "10",
    "Day": "13"
  },
  "Article": {
    "ArticleDate": [],
    "Language": [
      "eng"
    ],
    "ELocationID": [
      "10.1586/14787210.6.5.601"
    ],
    "Journal": {
      "ISSN": "1744-8336",
      "JournalIssue": {
        "Volume": "6",
        "Issue": "5",
        "PubDate": {
          "Year": "2008",
          "Month": "Oct"
        }
      },
      "Title": "Expert review of anti-infective therapy",
      "ISOAbbreviation": "Expert Rev Anti Infect Ther"
    },
    "ArticleTitle": "Current challenges in treating MRSA: what are the options?",
    "Pagination": {
      "StartPage": "601",
      "EndPage": "618",
      "MedlinePgn": "601-18"
    },
    "Abstract": {
      "AbstractText": [
        "This review looks at the challenges facing the worldwide community with the increasing problem of methicillin resistance in Staphylococcus aureus. The epidemiology and natural history of community-associated methicillin-resistant Staphylococcus aureus and the challenge of control is discussed. Options for treatment and review of key antimicrobial agents acting against methicillin-resistant S. aureus, both currently in use and in development, are addressed. There are a number of new agents, the place of which in therapeutic regimens is yet to emerge. The review attempts to inform the reader of the probable position of these agents."
      ]
    },
    "AuthorList": [
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Department of Microbiology, Sandwell and West Birmingham NHS Trust, Birmingham, UK."
          }
        ],
        "LastName": "Ratnaraja",
        "ForeName": "Natasha V D V",
        "Initials": "NV"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Hawkey",
        "ForeName": "Peter M",
        "Initials": "PM"
      }
    ],
    "PublicationTypeList": [
      "Journal Article",
      "Review"
    ]
  },
  "MedlineJournalInfo": {
    "Country": "England",
    "MedlineTA": "Expert Rev Anti Infect Ther",
    "NlmUniqueID": "101181284",
    "ISSNLinking": "1478-7210"
  },
  "ChemicalList": [
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Anti-Bacterial Agents"
    }
  ],
  "MeshHeadingList": [
    {
      "QualifierName": [
        "classification",
        "therapeutic use"
      ],
      "DescriptorName": "Anti-Bacterial Agents"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Clinical Trials as Topic"
    },
    {
      "QualifierName": [
        "drug therapy",
        "epidemiology",
        "microbiology",
        "prevention & control"
      ],
      "DescriptorName": "Community-Acquired Infections"
    },
    {
      "QualifierName": [
        "drug therapy",
        "epidemiology",
        "microbiology",
        "prevention & control"
      ],
      "DescriptorName": "Cross Infection"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Humans"
    },
    {
      "QualifierName": [
        "drug effects",
        "genetics",
        "pathogenicity"
      ],
      "DescriptorName": "Methicillin-Resistant Staphylococcus aureus"
    },
    {
      "QualifierName": [
        "drug therapy",
        "epidemiology",
        "microbiology"
      ],
      "DescriptorName": "Staphylococcal Infections"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Treatment Outcome"
    }
  ],
  "NumberOfReferences": "173"
}